Comparative studies on inhibitors of HIV protease: A target for drug design

In Silico Biology

Volumn 8, Issue 5-6, 2008, Pages 427-447

  Jayaraman, Sudha ^a   Shah, Kavita ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

HIV; In silico analysis; Mutation; Nelfinavir; Protease; Tipranavir

Indexed keywords

NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; TIPRANAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOINFORMATICS; COMPARATIVE STUDY; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CROSS REACTION; DRUG BINDING; DRUG DESIGN; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; VIRUS MUTANT; VIRUS MUTATION;

AMINO ACID SEQUENCE; BIOCATALYSIS; CATALYTIC DOMAIN; DRUG DESIGN; HIV; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; STRUCTURAL HOMOLOGY, PROTEIN; SUBSTRATE SPECIFICITY;

EID: 58149387580     PISSN: 13866338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and Lipman, D. J. (1990). Basic local alignment search tool. J. Mol. Biol. 215, 403-410.
2. Baldwin, J. J., Smith, G. and Springer, J. P. (1992). Chem. Des. Autom. News 7, 1.
3. Beerenwinkel, N., Sing, T., Lengauer, T., Rahnenführer, J., Roomp, K., Savenkov, I., Fischer, R., Hoffmann, D., Selbig, J., Korn, K., Walter, H., Berg, T., Braun, P., Fätkenheuer, G., Oette, M., Rockstroh, J., Kupfer, J., Kaiser, R. and Däumer, M. (2005). Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21, 3943-3950.
4. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. and Bourne, P. E. (2000). The protein data bank. Nucleic Acids Res. 28, 235-242.
5. Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer, E. F. Jr., Brice, M. D., Rodgers, J. R., Kennard, O., Shimanouchi, T. and Tasumi, M. (1977). The Protein Data Bank: A computer based archival file for macromolecular structures. J. Mol. Biol. 112, 535-542.
6. Blaney, J. M., Jorgensen, E. C., Connolly, M. L., Ferrin, T. E., Langridge, R., Oatley, S. J., Burridge, J. M. and Blake, C. C. F. (1982). Computer graphics in drug design: Molecular modeling of thyroid hormone-prealbumin interactions. J. Med. Chem. 25, 785-790.
7. Böhm, H.-J. (1992a). LUDI: Rule-based automatic design of mew substituents for enzyme inhibitor leads. J. Comput. Aided Mol. Des. 6 61-78.
8. Böhm, H.-J. (1992b). The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comp. Aided Mol. Des. 6, 593-606.
9. Bolon, D., Grant, R. A., Baker, T. A. and Sauer, R. T. (2005). Specificity versus staility in computational protein design. Proc. Natl. Acad. Sci. USA 102, 12724-12729.
10. Buchbinder, S. P., Katz, M. H., Hessol, N. A., O'Malley, P. M. and Holmberg, S. D. (1994). Long-term HIV-1 infection without immunologic progression. AIDS 8, 1123-1128.
11. Chan, D. C. and Kim, P. S. (1998). HIV entry and its inhibition. Cell 93, 681-684.
12. Coffin, J., Haase, A., Levy, J. A., Montagnier, L., Oroszlan, S., Teich, N., Temin, H., Toyoshima, K., Varmus, H., Vogt, P. and Weiss, R. A. (1986). What to call the AIDS virus? Nature 321, 10.
13. DesJarlais, R. L., Seibel, G. L., Kuntz, I. D., Furth, P. S., Alvarez, J. C., Ortiz de Montellano, P. R., DeCamp, D. L., Babé, L. M. and Craik, C. S. (1990). Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. USA 87, 6644-6648.
14. Freire, E. (2002). Designing drugs against heterogeneous targets. Nat. Biotechnol. 20, 15-16.
15. Freudenreich, C., Samama, J.-P. and Biellmann, J.-F. (1984). Design of inhibitors from the three dimensional structure of alcohol dehydrogenase. Chemical synthesis and enzymatic properties. J. Am. Chem. Soc. 106, 3344.
16. Gelderblom, H. R (1997). Fine structure of HIV and SIV. In: HIV Sequence Compendium (PDF format), Los Alamos National Laboratory (ed.),: Los Alamos National Laboratory, Los Alamos, New Mexico, pp. 31-44.
17. Goldblum, A. (1990). Modulation of the affinity of aspartic protease by the mutated residues in active site models. FEBS Lett. 261, 241-244.
18. Gottwein, E., Jäger, S., Habermann, A. and Kräusslich, H.-G. (2006). Cumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 gag cause a late budding defect. J. Virol. 80, 6267-6275.
19. Havranok, J. J. and Harbury, P. B. (2003). Automated design of specificity in molecular recognition. Nat. Struct. Biol. 10, 45-52.
20. Hornak, V. and Simmerling, C. (2007). Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov. Today 12, 132-138.
21. Ingr, M., Uhlíková, T., Strísovský, K., Majerová, E. and Konvalinka, J. (2003). Kinetics of the dimerization of retroviral proteases: The "fireman's grip" and dimerization. Protein Sci. 12 2173-2182.
22. Jiang, F. and Kim, S. H.(1991). "Soft-docking": Matching of molecular surface cubes. J. Mol. Biol. 219, 79-102.
23. Konvalinka, J., Löchelt, M., Zentraf, H., Flügel, R. M. and Kräusslich, H.-G. (1995). Active foamy virus proteinase is essential for virus infectivity but not for formation of a pol polyprotein. J. Virol. 69, 7264-7268.
24. Liu, Y. and Kuhlman, B. (2006). RosettaDesign server for protein design. Nucleic Acids Res. 34, W235-W238.
25. Mager, P. P. (2001). The active site of HIV-1 protease. Med. Res. Rev. 21, 348-353.
26. Mager, P. P., De Clercq, E., Froeyen, M. and Reinhardt, R. (2003). Interactions of the dimeric triad of HIV-1 aspartyl protease with inhibitors. Drug Des. Discov. 18, 53-64.
27. Miller, M., Schneider, J., Sathyanarayana, B. K., Toth, M. V., Marshall, G. R., Clawson, L., Selk, L., Kent, S. B. H. and Wlodawer, A. (1989). Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246, 1149-1152.
28. gag peptide. J. Biochem. 135, 447-453.
29. ausslich, H.-G. (2004). Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J. Vir. 78, 10803-10813.
30. Navia, M. A., Fitzgerald, P. M. D., McKeever, B. M., Leu, C. T., Heimbach, J. C., Herber, W. K., Sigal, I.S., Darke, P. L. and Springer, J. P. (1989). Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337, 615-620.
31. Perutz, M. F., Fermi, G., Abraham, D. J., Poyart, C. and Bursaux, E. (1986). Hemoglobin as a receptor of drugs and peptides: X-ray studies of the spectrochemistry of binding. J. Am. Chem. Soc. 108, 1064.
32. Plaskon, R. R., Kam, C. M., Burgess, E. M., Powers, J. C. and Suddath, F. L. (1992). Michaelis complexes of porcine pancreatic elastase with 7-[(alkylcarbomoyl) amino]-4-chloro-3-ethoxyisocoumarins: Translational sampling of inhibitor position and kinetic measurements. Proteins 13 141-151.
33. Schneidman-Duhovny, D., Inbar, Y., Nussinov, R. and Wolfson, H. J. (2005). PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Res. 33, W363-W367.
34. Sherman, W. and Tidor, B. (2008). Novel Method for probing the specificity binding profile of ligands: Application to HIV protease. Chem. Bio. Drug Des. 71, 387-407.
35. Sperka, T., Boross, P., Eizert, H., Tözsér, J. and Bagossi, P. (2006). Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease. Protein Eng. Des. Sel. 19, 369-375.
36. Tong, L. (2002). Viral Proteases. Chem. Rev. 102, 4606-4626.
37. Wlodawer, A., Miller, M., Jask'olksi, M., Sathyanarayana, B. K., Baldwin, E., Weber, I. T., Selk, L. M., Clawson, L., Schneider, J. and Kent, S. B. H. (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621.
38. Wyatt, R. and Sodroski, J. (1998). The HIV-1 envelope glycoproteins, fusogens, antigens, and immunogens. Science 280, 1884-1888.
39. Zhao, R. Y. and Elder, R. T. (2007). System and composition for isolating suppressors of HIV -Protease. Univ. of Maryland, Baltimore. USA. US Patent no.WO/2007/146802:IPC C12Q1/70(2006.01).
40. Zhang, D. W. and Zhang, J. Z. H. (2005). Full quantum mechanical study of binding of HIV-1 protease drugs. 103, 246-257.
41. Zheng, Y. H., Lovsin, N. and Peterlin, B. M. (2005). Newly identified host factors modulate HIV replication. Immunol. Lett. 97, 225-234.